Development of novel cell and gene therapies

$0ZIAFY2014CLNIH

Clinical Center

Investigators

Linked publications & trials

Paper 38374090 Paper 37939262 Paper 37394115 Paper 36099324 Paper 34302788 Paper 33993466 Paper 33956057 Paper 33823169 Paper 33764809 Paper 33632869 Paper 33558725 Paper 33472742 Paper 33232788 Paper 32612991 Paper 32286905 Paper 31278568 Paper 31178392 Paper 30871636 Paper 30012146 Paper 29812997 Paper 29540180 Paper 29368612 Paper 29155426 Paper 28447618 Paper 28295178 Paper 28236305 Paper 27412889 Paper 27226436 Paper 27210719 Paper 26823601 Paper 26505619 Paper 26190358 Paper 26116089 Paper 26071480 Paper 25937830 Paper 25882666 Paper 25532725 Paper 25452614 Paper 25319501 Paper 25223845 Paper 25188417 Paper 25064527 Paper 24844857 Paper 24573369 Paper 24452962 Paper 24422625 Paper 24368014 Paper 24117879 Paper 23992830 Paper 23813900 Paper 23426943 Paper 23148746 Paper 23109243 Paper 22586033 Paper 22547579 Paper 22421946 Paper 22420641 Paper 22309358 Paper 22272697 Paper 22185188 Paper 21740581 Paper 21684345 Paper 21684344 Paper 21501511 Paper 21304401 Paper 21258790 Paper 20635956 Paper 20628641 Paper 20350323 Paper 20078383 Paper 19776705 Paper 19431094 Paper 19342965 Paper 18676758

Abstract

The cell processing laboratory is developing new natural killer (NK) cell, dendritic cell (DC), bone marrow stromal cell (BMSC) and chimeric antigen receptor (CAR) T cell therapies. NK cells are an important part of the innate immune system and they are thought play an important in host defense against foreign and abnormal cells including cancer and hematological malignancies. Preliminary work suggests that hematological malignancies can be treated by the administration of NK cells. The Cell Processing Laboratory has been expanding autologous and allogeneic NK cells to treat Clinical Center patients with cancer and hematological malignancies. Dendritic cells (DCs) are an important adjuvant for cancer vaccines. The Cell Processing Laboratory is currently is producing DCs expressing HER2/neu to treat cancer patients whose tumor express this antigen and is developing a new protocol to treat patients with stage 0 prostate cancer Bone marrow stromal cells (BMSCs) can inhibit in function and support tissue regeneration Preliminary studies suggest that acute graft versus host disease and autoimmune diseases can be treated with BMSCs. In addition, BMSCs secrete cytokines and growth factor that improve the healing of damaged tissue and BMSCs have used to treat patients with ischemic heart disease and peripheral vascular disease. The Cell Processing Laboratory has developed a bank of BMSCs products collected from healthy subjects that is being used to treat hematopoietic stem transplant patients with acute graft versus host disease or graft failure and inflammatory bowel disease. The lab has also developed a process to produce autologous BMSCs to treat patients with ischemic heart disease. The cell processing laboratory has developed CAR T cells expressing anti-CD19. These cells are now being used to treat pediatric patents with B cell leukemias. The laboratory has also developed and is manufacturing anti-GD2 CAR T cells to treat patients with sarcoma and anti-B Cell Maturation Antigen (BCMA) to treat patients with multiple myeloma. A process to manufacture anti-CD22 CAR T cells in underdevelopment.

View original record on NIH RePORTER →